Company intelligence / Profile preview
SunVax mRNA Therapeutics
Beverly, Massachusetts, United Statessunvaxmrna.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
SunVax has developed LNP-samRNA therapy showing remarkable efficacy in animal models with tumor-free rates of up to 80% in B16F10 models. Their RSV vaccine has demonstrated comparable performance to Moderna's and GSK's RSV vaccines.
- Therapeutic areas
- OncologyRare DiseasesImmunologyInfectious Diseases
- Modalities
- mRNA therapeuticsself-amplifying mRNA (samRNA)lipid nanoparticle (LNP) delivery technology
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Development partners mentioned but not specifically named
Beyond the preview
Go deeper on SunVax mRNA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SunVax mRNA Therapeutics.